Severe Covid‐19 and acute pulmonary hypertension: 24‐month follow‐up regarding mortality and relationship to initial echocardiographic findings and biomarkers
Authors' conclusion
The mortality risk was increased up to 24 months after the initial examination in ICU-treated Covid-19 patients with a TTE diagnosis of aPH, compared to non-aPH patients. Certain individual TTE parameters were able to discriminate 24-month risk of morality.
Study context
- Population
- Intensive care unit (ICU)-treated Covid-19 patients with ICU trans-thoracic echocardiography
- Participants
- 67 patients
- Exposure
- Acute pulmonary hypertension vs non-aPH on ICU trans-thoracic echocardiography (TTE)
- Outcome
- Mortality
- Follow-up
- 1-24-month period following TTE diagnosis
Methodological detailselectronic medical chart-based follow-up
- Electronic medical chart-based follow-up
Main finding
As reported in the abstract
Overall mortality · up to 24 months
Observational data: associations, not effects.
Further findings
Mortality during the 1-24-month period
Mortality during the 1-24-month period
- Increased relative mortality risk continued in acute pulmonary hypertension (aPH) vs non-aPH
Tricuspid valve regurgitation allowing systolic pulmonary artery pressure measurement (K-M)
- Associated with a similar K-M outcome as the aPH diagnostic criteria (systolic pulmonary artery pressure >35 mmHg)
NTproBNP and Troponin-T at time of TTE (ROC)
- No clinically useful ROC analysis data
Original publication
Severe Covid‐19 and acute pulmonary hypertension: 24‐month follow‐up regarding mortality and relationship to initial echocardiographic findings and biomarkers. Acta Anaesthesiol Scand. Published 28 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →